NO894946D0 - Fremgangsmaate for redusering av vevsskade paa et betennelsessted ved anvendelse av et monoklonalt antistoff. - Google Patents

Fremgangsmaate for redusering av vevsskade paa et betennelsessted ved anvendelse av et monoklonalt antistoff.

Info

Publication number
NO894946D0
NO894946D0 NO894946A NO894946A NO894946D0 NO 894946 D0 NO894946 D0 NO 894946D0 NO 894946 A NO894946 A NO 894946A NO 894946 A NO894946 A NO 894946A NO 894946 D0 NO894946 D0 NO 894946D0
Authority
NO
Norway
Prior art keywords
monoclonal antibody
reducing tissue
bottle
procedure
application
Prior art date
Application number
NO894946A
Other languages
English (en)
Other versions
NO894946L (no
Inventor
Robert F Todd Iii
Paul J Simpson
Benedict R Lucchesi
Stuart F Schlossman
James D Griffin
Original Assignee
Univ Michigan
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/061,336 external-priority patent/US4840793A/en
Application filed by Univ Michigan, Dana Farber Cancer Inst Inc filed Critical Univ Michigan
Publication of NO894946D0 publication Critical patent/NO894946D0/no
Publication of NO894946L publication Critical patent/NO894946L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
NO89894946A 1987-06-11 1989-12-08 Fremgangsmaate for redusering av vevsskade paa et betennelsessted ved anvendelse av et monoklonalt antistoff. NO894946L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/061,336 US4840793A (en) 1987-06-11 1987-06-11 Method of reducing tissue damage at an inflammatory site using a monoclonal antibody
US07/165,025 US4935234A (en) 1987-06-11 1988-03-07 Method of reducing tissue damage at an inflammatory site using a monoclonal antibody
PCT/US1988/001928 WO1988009672A1 (en) 1987-06-11 1988-06-03 Method of reducing tissue damage at an inflammatory site using a monoclonal antibody

Publications (2)

Publication Number Publication Date
NO894946D0 true NO894946D0 (no) 1989-12-08
NO894946L NO894946L (no) 1990-01-23

Family

ID=26740960

Family Applications (1)

Application Number Title Priority Date Filing Date
NO89894946A NO894946L (no) 1987-06-11 1989-12-08 Fremgangsmaate for redusering av vevsskade paa et betennelsessted ved anvendelse av et monoklonalt antistoff.

Country Status (12)

Country Link
US (1) US4935234A (no)
EP (1) EP0371036B1 (no)
JP (1) JPH02503796A (no)
CN (1) CN1034055C (no)
AT (1) ATE126703T1 (no)
AU (1) AU621304B2 (no)
BR (1) BR8807559A (no)
CA (1) CA1317880C (no)
DE (1) DE3854351T2 (no)
DK (1) DK620089A (no)
NO (1) NO894946L (no)
WO (1) WO1988009672A1 (no)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019648A (en) * 1987-07-06 1991-05-28 Dana-Farber Cancer Institute Monoclonal antibody specific for the adhesion function domain of a phagocyte cell surface protein
US5395929A (en) * 1987-12-15 1995-03-07 Dana Farber Cancer Institute Isolated nucleic acid encoding the alpha subunit of the human leukocyte adhesion receptor
US4986979A (en) * 1989-03-14 1991-01-22 Neorx Corporation Imaging tissue sites of inflammation
WO1990013316A1 (en) * 1989-04-28 1990-11-15 Baylor College Of Medicine Dissemination of hiv-1 infected cells
WO1992003473A1 (en) * 1990-08-27 1992-03-05 Cetus Corporation Cd18 peptide medicaments for the treatment of disease
WO1992006697A1 (en) * 1990-10-23 1992-04-30 Repligen Corporation Anti-inflammatory composition
WO1992011870A1 (en) * 1991-01-11 1992-07-23 Repligen Corporation Method of preventing inflammatory damage
US5322699A (en) * 1991-02-04 1994-06-21 The Rockefeller University Leukocyte-derived CR3 modulator, integrin modulating factor-1 (IMF-1)
GB9115364D0 (en) * 1991-07-16 1991-08-28 Wellcome Found Antibody
US5708141A (en) * 1992-05-11 1998-01-13 Corvas International, Inc. Neutrophil inhibitors
PT642577E (pt) * 1992-05-22 2004-08-31 Univ Montana State Anticorpos com especificidade para moleculas de adesao multipla
CA2144738A1 (en) * 1992-10-09 1994-04-28 Michael Diamond A subpopulation of mac-1 (cd11b/cd18) molecules which mediate neutrophil adhesion to icam-1 and fibrinogen
GB9312315D0 (en) * 1993-06-15 1993-07-28 Poston Robin Leukocyte adhesion assay
US6884590B1 (en) 1994-02-11 2005-04-26 Cedars-Sinai Medical Center Methods of screening for ulcerative colitis and crohn's disease
US5681699A (en) * 1994-02-11 1997-10-28 Cedars-Sinai Medical Center Methods of diagnosing ulcerative colitis and Crohn's disease
US5656441A (en) * 1994-04-19 1997-08-12 Trustees Of Boston University Methods for determining cellular adhesion
US5797870A (en) * 1995-06-07 1998-08-25 Indiana University Foundation Pericardial delivery of therapeutic and diagnostic agents
US6001356A (en) * 1995-09-29 1999-12-14 Rush-Presbyterian-St. Luke's Medical Center Method of inhibiting tissue destruction in autoimmune disease using anti-CD44 antibodies
US5914112A (en) * 1996-01-23 1999-06-22 Genentech, Inc. Anti-CD18 antibodies in stroke
US20020081294A1 (en) * 1996-01-23 2002-06-27 Genentech, Inc. Co-administration of a thrombolytic and an anti-CD18 antibody in stroke
AU4000500A (en) * 1999-02-17 2000-09-04 Genentech Inc. Co-administration of a thrombolytic and an anti-cd18 antibody
WO2001070266A2 (en) 2000-03-17 2001-09-27 Millennium Pharmaceuticals, Inc. Method of inhibiting stenosis and restenosis with a mixture of antibodies anti cd18 and anti ccr2
US8914114B2 (en) 2000-05-23 2014-12-16 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
EP1487494A2 (en) * 2002-02-26 2004-12-22 North Shore-Long Island Jewish Research Institute Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors
AU2005225458B2 (en) 2004-03-25 2008-12-04 The Feinstein Institutes For Medical Research Neural tourniquet
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
EP2270512B1 (en) * 2004-12-08 2016-03-23 Cedars-Sinai Medical Center Methods for diagnosis of Crohn's disease
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
CN101124012B (zh) 2004-12-27 2012-09-05 范因斯坦医学研究院 通过电刺激迷走神经治疗炎症性疾病的装置
US20100021917A1 (en) * 2007-02-14 2010-01-28 Cedars-Sinai Medical Center Methods of using genes and genetic variants to predict or diagnose inflammatory bowel disease
US20100190162A1 (en) * 2007-02-26 2010-07-29 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
WO2010039931A2 (en) * 2008-10-01 2010-04-08 Cedars-Sinai Medical Center Methods of using il17rd and il23-il17 pathway genes to diagnose crohn's disease
WO2008137762A2 (en) * 2007-05-04 2008-11-13 Cedars-Sinai Medical Center Methods of diagnosis and treatment of crohn's disease
US20100015156A1 (en) * 2007-03-06 2010-01-21 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease in children
US8486640B2 (en) 2007-03-21 2013-07-16 Cedars-Sinai Medical Center Ileal pouch-anal anastomosis (IPAA) factors in the treatment of inflammatory bowel disease
US20100184050A1 (en) * 2007-04-26 2010-07-22 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease in the puerto rican population
WO2009029614A1 (en) * 2007-08-27 2009-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
WO2009146030A1 (en) * 2008-03-31 2009-12-03 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of t-cell activity
US20110189685A1 (en) * 2008-10-22 2011-08-04 Cedars-Sinai Medical Center Methods of using jak3 genetic variants to diagnose and predict crohn's disease
WO2010059617A2 (en) 2008-11-18 2010-05-27 Setpoint Medical Corporation Devices and methods for optimizing electrode placement for anti-inflamatory stimulation
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
WO2010075579A2 (en) 2008-12-24 2010-07-01 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (mr-uc) requiring colectomy
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US20110054569A1 (en) * 2009-09-01 2011-03-03 Zitnik Ralph J Prescription pad for treatment of inflammatory disorders
US8886339B2 (en) 2009-06-09 2014-11-11 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
WO2014169145A1 (en) 2013-04-10 2014-10-16 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
AU2010336337B2 (en) 2009-12-23 2016-02-04 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
WO2012154865A2 (en) 2011-05-09 2012-11-15 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
KR20210157418A (ko) 2013-03-27 2021-12-28 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
EP4105236A1 (en) 2013-07-19 2022-12-21 Cedars-Sinai Medical Center Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
US11406833B2 (en) 2015-02-03 2022-08-09 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
WO2017127758A1 (en) 2016-01-20 2017-07-27 Setpoint Medical Corporation Implantable microstimulators and inductive charging systems
WO2017127756A1 (en) 2016-01-20 2017-07-27 Setpoint Medical Corporation Control of vagal stimulation
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
EP3430172A4 (en) 2016-03-17 2019-08-21 Cedars-Sinai Medical Center METHOD FOR DIAGNOSIS OF INFLAMMATORY ENDURANCE THROUGH RNASET2
EP3668402A4 (en) 2017-08-14 2021-05-19 Setpoint Medical Corporation VAGUS NERVOUS STIMULATION PRE-SCREENING TEST
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
KR20230012585A (ko) 2020-05-21 2023-01-26 더 파인스타인 인스티튜츠 포 메디칼 리서치 미주 신경 자극을 위한 시스템들 및 방법들

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4840793A (en) * 1987-06-11 1989-06-20 Dana-Farber Cancer Institute Method of reducing tissue damage at an inflammatory site using a monoclonal antibody

Also Published As

Publication number Publication date
AU1946388A (en) 1989-01-04
AU621304B2 (en) 1992-03-12
NO894946L (no) 1990-01-23
EP0371036B1 (en) 1995-08-23
DE3854351T2 (de) 1996-03-21
WO1988009672A1 (en) 1988-12-15
DK620089A (da) 1990-02-07
CA1317880C (en) 1993-05-18
DE3854351D1 (de) 1995-09-28
US4935234A (en) 1990-06-19
EP0371036A1 (en) 1990-06-06
ATE126703T1 (de) 1995-09-15
BR8807559A (pt) 1990-05-22
EP0371036A4 (en) 1990-06-27
CN1033242A (zh) 1989-06-07
DK620089D0 (da) 1989-12-08
JPH02503796A (ja) 1990-11-08
CN1034055C (zh) 1997-02-19

Similar Documents

Publication Publication Date Title
NO894946D0 (no) Fremgangsmaate for redusering av vevsskade paa et betennelsessted ved anvendelse av et monoklonalt antistoff.
NL970045I2 (nl) Desulfatohirudinen, werkwijze voor hun bereiding en farmaceutische middelen.
NO982062L (no) Humaniserte antistoff mot humant gp39, sammensetninger inneholdende dette, samt terapeutisk anvendelse derav
NL186846C (nl) Waterig preparaat voor de behandeling van vezelig materiaal, en werkwijze voor het behandelen van vezelig materiaal.
ATA29495A (de) Zusammensetzung und verfahren zur prävention und behandlung von entzündungen mit immunglobulin a
EP0313378A3 (en) Methods and compositions for transient elimination of humoral immune antibodies
DE69027220D1 (de) Zusammensetzung und verfahren zur behandlung von schmerzvollen entzündlichen oder allergischen erkrankungen
ATE104852T1 (de) Verwendung von bicyclischen imidazol-verbindungen zur behandlung von hyperaldosteronismus.
NO894222D0 (no) Fremgangsmaater for behandling av profylakse av pneumocytis carinii pneumoni og andre sykdommer og forbindelser og formuleringer til anvendelse i nevnte metoder.
Mebs et al. Snake venom hemorrhagins: neutralization by commercial antivenoms
Paronetto et al. Immunologic observations on homografts: I. The canine liver
Ueda et al. Experimental gold nephropathy in guinea pigs: detection of autoantibodies to renal tubular antigens
ATE55059T1 (de) Verfahren zur inaktivierung von unvertraeglichkeitsreaktionen verursachenden substanzen.
NL187299B (nl) Gevormde farmaceutische doseringseenheid voor het behandelen van hart- en vaatziekten.
Van Amerongen et al. Immunofluorescent localization and extractability of fibronectin in human dental pulp
DE60045638D1 (de) Vermeidung und behandlung von krankheiten, die mit der blutgerinnung in zusammenhang stehen
ATE167628T1 (de) Verfahren und zusammensetzungen zur behandlung von krankheiten verbunden mit mangelhaften immunfunktion
NL7902450A (nl) Farmaceutisch preparaat met anti-complementaire wer- king, werkwijze voor de bereiding daarvan alsmede werk- wijze voor het behandelen van nephritis.
JPS58501543A (ja) ヒトインタ−フエロン蛋白とヒトインタ−フエロン蛋白に対する抗体に関する改良
IE811612L (en) Thiazoles
Connell et al. Allotype suppression in rabbits: the requirement for CH3 domain of anti-allotype antibody
DE69112718D1 (de) Verfahren und Zusammensetzung zur Behandlung von tierischen Exkrementen.
Yamaguchi et al. Bence-Jones Protein λ-type Multiple Myeloma Patient Withdrawn from Maintenance Hemodialysis after Long-term Bortezomib and Dexamethasone Therapy
Koyama et al. Platelet involvement in the nephritis of acute serum sickness in rabbits: protection by dipyridamole and FUT-175.
Dioguardi et al. Residual Antigenicity of Lyophilized Porcine Skin Shown in vitro by Immunological Methods